Artivion, Inc. (CYL.F)

19.38 +0.06 (+0.31%) As of 08:01AM CEST. Market open.

Artivion, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
https://artivion.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 1,500

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James Patrick Mackin	Chairman, President & CEO	2.22M	181.84k	1967
Mr. Lance A. Berry CPA	Executive VP of Finance, COO & CFO	129.27k	N/A	1972
Ms. Amy D. Horton CPA	VP & Chief Accounting Officer	580.47k	110.44k	1970
Ms. Jean F. Holloway Esq.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	786.18k	N/A	1957
Mr. John E. Davis	Senior VP & Chief Commercial Officer	749.35k	25.74k	1965
Mr. Matthew A. Getz	VP of Human Resources & Chief Human Resources Officer	N/A	N/A	1969
Dr. Marshall S. Stanton M.D.	Senior VP of Clinical Research & Chief Medical Officer	575.13k	N/A	1957
Dr. Robert C. Thomson	Vice President of Research & Development	N/A	N/A	1970
Mr. Florian Tyrs	Vice President of Global Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Corporate Governance

Artivion, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.